Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linerixibat and Obeticholic Acid DDI Study
NCT04053023Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linerixibat in cholestatic pruritus and primary biliary cholangitis (PBC), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Total-OCA at Steady State at Day 38, Area Under the Concentration-time Curve From Time 0 to 24 Hour for Total-OCA at Steady State and 2 more. Started Aug 2019; status: completed.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritusprimary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04053023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053023.